Extended Data Fig. 3: Lysophosphatidylcholines (lysoPCs) are associated with clinical AD and biomarker-supported AD (defined by either P-tau181 or P-tau217).
From: Lysophosphatidylcholines are associated with amyloidosis in early stages of Alzheimer’s disease
The odds ratio (point) and confidence interval (whiskers) of PC1–5 in relation to clinical AD and biomarker-supported AD, defined as P-tau181 supported AD or P-tau217 supported AD, stratified by APOE ε4 allele status. An * indicates p value < 0.05. Similar trends in association are seen between lysoPC constructs and P-tau181 or P-tau217 supported AD within each APOE ε4 strata.
